3 days popular7 days popular1 month popular3 months popular

Side Effect Of Retinal Detachment May Be Prevented By Ranibizumab

Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of . PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual’s quality of life. Each year 55,000 people are at risk for developing PVR in the United States alone.

A new study carried out by scientists from The and Ear and the Department of Ophthalmology, , and published on The American Journal of Pathology website and scheduled for the May 2013 print edition, suggests that Ranibizumab, an anti-VEGF-A monoclonal antibody fragment, is a potential prophylaxis for PVR.

“In this manuscript we present basic studies that have clear implications for and therapy,” said senior author , Ph.D, Senior Scientist and Sinon Scholar in Retinal Research, Mass. Eye and Ear/Schepens Eye Research Institute and Professor of Ophthalmology, Harvard Medical School.

Researchers found that the putative mediators of PVR pathogenesis are , which contribute to common diseases such as atherosclerosis and cancer. “Consequently, elucidating functional relationships between and resolving their contribution to pathogenesis is of wide interest because such information will substantially advance our ability to combat a broad spectrum of diseases,” Dr. Kazlauskas said.

While investigating the functional relationships between growth factors known to promote pervasive human diseases, researchers discovered that Ranibizumab reduced the bioactivity of vitreous from patients and experimental animals with PVR, and protected rabbits from developing this disease.

These pre-clinical findings suggest that one of the clinically approved approaches to neutralize VEGF-A constitutes a novel prophylactic for an incurable, blinding disease.

“Our discoveries also raise the provocative idea that anti-VEGF-based therapies may be effective for managing more than the angiogenesis- and vascular-permeability-driven pathological conditions,” Dr. Kazlauskas continues.

Source

This study was funded by the NIH/National Eye Institute (EY022970), the Massachusetts Lions Foundation, the Department of Defense (WB1XWH-10-1-0392) and Canadian Institutes of Health Research (CIHR).
The full list of collaborators is available in the manuscript.
Massachusetts Eye and Ear Infirmary